BAM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Brookfield Asset Management (BAM) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown impressive revenue and net income growth in its latest quarter, the technical indicators and options data suggest a lack of strong upward momentum. Additionally, analyst ratings are mixed, and there are no significant recent trading signals or influential political activity to suggest a compelling entry point. Given the user's impatience and unwillingness to wait for optimal entry points, holding off on purchasing this stock for now is advisable.
The technical indicators for BAM are currently bearish. The MACD histogram is negative (-0.314) and contracting, the RSI is neutral at 39.261, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 48.011, with key support at 45.771 and resistance at 50.251.
The company has launched a commercial paper program to enhance liquidity, allowing for up to $1 billion in unsecured notes.
BAM is highlighted as a stable dividend stock for long-term income, with an implied 4% dividend yield.
Strong financial performance in Q4 2025, with revenue up 1061.67% YoY and net income up 201.08% YoY.
Analysts have mixed ratings, with several firms lowering price targets recently.
Technical indicators show bearish trends, with the stock trading below key moving averages.
Broader market sentiment is negative, as evidenced by the S&P 500's decline of -0.56%.
In Q4 2025, Brookfield Asset Management reported exceptional revenue growth of 1061.67% YoY, reaching $1.394 billion. Net income increased by 201.08% YoY to $560 million. However, EPS dropped by -20.93% YoY to 0.34, indicating potential dilution or higher expenses. Gross margin remained unchanged.
Analyst ratings are mixed. While some firms like BMO Capital upgraded the stock to Outperform, others like UBS and Scotiabank lowered their price targets. The consensus reflects cautious optimism, with price targets ranging from $52 to $75. Analysts highlight the company's strong fundamentals but note challenges in valuation and market conditions.
